Susanna Ulahannan
Director, Oklahoma TSET Phase 1 Program · University of Oklahoma College of Medicine
Credentials: · · · · · · ·
History
- Present
NRG Oncology Immunotherapy Subcommittee Department
- Present
OU College of Medicine
- 2004–2007
- 2003–2004
- 1998–2002
- 2001
Sahlgrenska Akademin, Goteborg University
Research
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Journal of Hepatology · 2017 · 660 citations
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States
Cancer · 2016 · 272 citations
Nature Medicine · 2023 · 132 citations
- AD
9 papers
8 papers
- AS
8 papers
8 papers
7 papers
7 papers
- OC
7 papers · 6 as a fellow
6 papers · 6 as a resident
Grants
- 2018–2028
Stephenson Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $85.6K · University of Oklahoma Hlth Sciences Ctr
Clinical trials
- 2026–2030
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Principal investigator · Not yet recruiting · Phase 1
University of Oklahoma
- 2025–2026
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
- 2024–2026
Pilot Window of Opportunity Trial (POET)
Principal investigator · Active not recruiting · Phase 2
University of Oklahoma
- 2021–2028
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Principal investigator · Recruiting · Phase 1, Phase 2
Artios Pharma Ltd